Breckenridge Pharmaceutical, Inc.

Breckenridge Pharmaceutical Inc. is a privately held pharmaceutical company that develops and markets generic drugs in the United States. Founded in 1983, it is the American affiliate of Towa International, based in Barcelona, Spain. The company's headquarters are located in Berkeley Heights, New Jersey. Breckenridge Pharmaceutical employs approximately 71 to 81 individuals and reports annual revenues in the range of $10 million to $50 million.

Breckenridge Pharmaceutical focuses on providing high-quality and cost-effective generic prescription products across various therapeutic categories. Its product lines include tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmic powders, nasal sprays, and injectable products. The company engages in organic product development and forms strategic partnerships with manufacturers globally to expand its portfolio. Recent collaborations aim to strengthen its presence in the hospital market with sterile injectable products.

Breckenridge Pharmaceutical's patent litigation posture indicates it operates as a defendant, defending against patent challenges. The company has one tracked case, where it appears as a defendant in a Patent Trial and Appeal Board (PTAB) proceeding.

The notable case, Unified Patents, LLC v. Breckenridge Pharmaceutical Inc., initiated in 2024, is before the PTAB. Unified Patents is an organization known for challenging patents, often those asserted by Non-Practicing Entities (NPEs), by filing inter partes reviews (IPRs) to deter what it considers low-quality patents. This indicates that Breckenridge Pharmaceutical is an operating company whose patents are being challenged. Breckenridge has also been involved in district court patent litigation in the past, such as cases concerning obvious-type double patenting (ODP) issues.